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Abstract 
The metabolic syndrome (MS) in adults is
defined as a concurrence of obesity, disturbed
glucose and insulin metabolism, hypertension
and  dyslipidemia,  and  is  associated  with
increased morbidity and mortality from cardio-
vascular diseases and type 2 diabetes. Studies
now indicate that many of its components are
also  present  in  children  and  adolescents.
Moreover, the clustering of these risk factors
has been documented in some children, who
are at increased cardiovascular risk in adult-
hood. The MS is highly prevalent among over-
weight  children  and  adolescents.  Identifying
these children is important for early preven-
tion and treatment of different components of
the  syndrome.  The  first-line  treatment  com-
prises lifestyle modification consisting of diet
and exercise. The most effective tool for pre-
vention of the MS is to stop the development of
childhood obesity. The first attempt at consen-
sus-based  pediatric  diagnostic  criteria  was
published  in  2007  by  the  International
Diabetes  Federation.  Nevertheless,  national
prevalence  data,  based  on  uniform  pediatric
definition,  protocols  for  prevention,  early
recognition  and  effective  treatment  of  pedi-
atric MS are still needed. 
The aim of this article is to provide a short
overview  of  the  diagnosis  and  treatment
options of childhood MS, as well as to present
the relationships between MS and its individ-
ual components.   
Introduction
More than 20 years have passed since the
first description of metabolic syndrome (MS)
in  adults.
1 During  this  time,  many  expert
groups have proposed definitions of MS, with
some common characteristics and some differ-
ences.
2-5 The purpose of these definitions has
been  to  determine  which  patients  are  at
increased cardiovascular (CV) risk. At present
the view held is that in each adult patient with
a single CV risk factor, all the other known risk
factors have to be looked for and individually
treated.
6,7 On the other hand, in children, till
now, only one consensus-based definition of
pediatric  MS  has  been  published,
8 although
many studies have shown that MS and its com-
ponents do appear in childhood.
9 In fact, their
prevalence  is  on  the  increase,
10,11 mostly  on
account of obesity.
12,13 Obesity and the closely
linked insulin resistance are presumed to play
a  central  role  in  the  development  of  MS.
14,15
Many studies have also shown that clustering
of CV risk factors continues into adulthood
16
and predicts the risk of future CV events and
diabetes.
17,18 In  numerous  epidemiological
studies, the negative influence of MS on CV
morbidity and mortality and on type 2 diabetes
has been documented.
19,20 On the other hand,
lower CV risk and prevalence of MS have been
established  in  children  and  adults  with  MS
components in the lower normal range, inde-
pendent of a positive family history of CV dis-
ease  (clinical  marker  of  genetic  predisposi-
tion).
21,22 This further indicates the important
role of a healthy lifestyle in early childhood in
the prevention of CV diseases.
In this review article we describe definitions
of MS, discuss its pathophysiology, point out
the management and treatment options, and
present  physiological  mechanisms  between
MS and its constitutive elements. 
Definition of metabolic syndrome
MS was first described by Reaven.
1 In subse-
quent years different names have been used,
namely, dysmetabolic syndrome, syndrome X,
cardiometabolic syndrome, deadly quartet and
insulin  resistance  syndrome.
15 Most  studies
performed in recent years have used defini-
tions published by the World Health Organiz-
ation (WHO)
2 and by the National Cholesterol
Education Program/Adult Treatment Panel III
(NCEP/ATP III),
3 which was later revised.
4 A
similar definition was adopted in 2005 by the
International Diabetes Federation (IDF).
5 The
most often used definitions are presented in
Table 1.
2,3,5,23
Two years later, the first consensus-based
definition  of  MS  in  children  was  published
8
(Table 2), whether it unifies the field remains
to  be  seen.  Namely,  in  pediatric  studies  as
many as 40 different definitions of MS have
been applied.
24 Some of them are presented in
Table 3;
11,25-27 for the whole list of studies some
good reviews are available.
24,28
Most researchers have used adapted defini-
tions of MS in adults, especially NCEP/ATP III
3
and the World Health Organization,
2 with com-
ponents of MS adjusted according to age and
percentile values.
25-27,29 Difficulties in defining
the MS in children arise from their different
growth  patterns,  from  the  influence  of  hor-
monal changes in puberty on insulin resist-
ance and lipid profiles, and from ethnic differ-
ences.
14 Additionally, there has been no univer-
sal agreement about which level of particular
component to use for the criteria. Instead, val-
ues above the 85
th, 90
th, 95
th, 97
th and even 75
th
percentile for age and gender have been used
(Table  3).  For  this  reason,  comparison
between  studies  is  difficult.    Recently,  first
studies  using  pediatric  IDF  definition  have
been published.
30,31
In addition to five components of the clinical
definition of MS, there are numerous associat-
ed findings, including procoagulant and proin-
flammatory states
15,32(Table 4).
Prevalence of metabolic syndrome
The prevalence of MS in adults, according to
the NCEP/ATP III, was found to be around 15%
in  Europe
33 and  24%  in  the  United  States,
34
respectively, most probably due to obesity and
unhealthy lifestyles in the latter. Many studies
showed that MS prevalence is highly depend-
ent  on  the  definition  used.
35-37 Prevalence
results of studies, comparing WHO with the
NCEP/ATP III definition, were mostly similar,
36
whereas in most studies using the IDF defini-
tion,  the  prevalence  was  higher,
36 reaching
even 43.4%.
37 The situation is similar in the
pediatric  population,  where  the  increasing
prevalence of obesity,
13 as well as obesity-relat-
ed diseases, such as hypertension,
10 type 2 dia-
betes
38 and CV diseases,
39 was established. For
American children, the prevalence of MS was
found to be 9.2% in the period from 1988 to
1994 and 12.7% from 1999 to 2000. During this
period, the percentage of children with a body
mass index above the 85
th percentile increased
from 25.9 to 30.5%.
11 In most other studies, the
prevalence of MS in the general pediatric pop-
ulation was lower for both American and other
pediatric  patients,
28,40 dependent  not  only  on
definition but also on the percentile cut-offs
used.
41 In the study of Goodman et al., preva-
lence,  using  ATP  III  and  WHO  criteria,  was
found to be 4.2% and 8.4%,  respectively.
27 In
studies using pediatric IDF definition, preva-
lence for American adolescents was found to
be 4.5%
30 and 2.4% for Finnish adolescents.
31 In
obese  children,  the  prevalence  is  30%
25 and
reaches 50% in extremely obese children.
26
Pediatric Reviews 2009;volume 1:e1
Correspondence: Natasa Marcun Varda,
Department of Pediatrics, University Medical
Centre Maribor, Ljubljanska 5, 2000 Maribor,
Slovenia. E-mail: natasa.marcunvarda@amis.net
Key words: metabolic syndrome, cardiovascular
diseases, obesity, child, prevention, treatment.
Received for publication: 30 January 2009.
Revision received: 5 May 2009.
Accepted for publication: 15 May 2009.
This work is licensed under a Creative Commons
Attribution 3.0 License (by-nc 3.0)
©Copyright N. Marcun Varda, A. Gregoric 2009
Licensee PAGEPress, Italy
Pediatric Reviews 2009;1:e1
doi:10.4081/pr.2009.e1[page 2] [Pediatric Reviews 2009;1:e1]
Like  many  other  countries,  we  have  no
national prevalence data on MS in our country.
This  is  an  important  task  for  the  future.
Nevertheless, we have been able to conduct a
study on prevalence of MS in our children with
essential hypertension and MS was diagnosed
in  19.2%  (NCEP/ATPIII)  and  14.4%  (IDF)  of
hypertensives, respectively, which is compara-
ble with other similar studies.
42
Pathophysiology of metabolic 
syndrome
In  contrast  to  adults,  pathophysiological
mechanisms  for  MS  in  children  have  been
poorly investigated. The central role of insulin
resistance has been proposed, although other
mechanisms are also involved.
15 Resistance to
the actions of insulin on carbohydrate and lipid
metabolism can explain all components of MS,
and in part, atherogenesis
43 (Table 5). 
There  are  also  an  increasing  number  of
studies investigating novel biological actions
of insulin, which have shown that hyperinsu-
linemia itself contributes to atherogenecity.
43
The important role of free fatty acids in insulin
resistance through specific actions that block
insulin  signal  transduction  should  also  be
stressed. In addition, they contribute to induc-
tion of oxidative stress, inflammation and sub-
normal vascular reactivity.
44 According to the
inflammatory hypothesis, the proinflammatory
state in obesity influences insulin resistance
and MS.
43Both free fatty acids and inflammato-
ry cytokines are involved in insulin resistance,
the development of a prothrombotic and proin-
flammatory state, and in atherogenesis.
Obesity and metabolic syndrome
The mechanism of the influence of obesity
on CV diseases and type 2 diabetes is present-
ed in Figure 1.
14 Obesity is closely related to
insulin resistance, the most common abnor-
mality  seen  in  obesity.  In  obesity,  enlarged
adipocytes  produce  more  proinflammatory
cytokines, such as tumor necrosis factor-α and
interleukin-6, and less anti-inflammatory pep-
tides, such as adiponectin.
45 Childhood obesity
which progresses into adulthood is associated
with  a  higher  morbidity  and  mortality  than
adult-onset obesity.
46 In addition to genetic fac-
tors, obesity is the most important risk factor
Review
Table  1.  Definition  of  metabolic  syndrome  according  to  the World  Health  Organization  (WHO),
2 the  National  Cholesterol  Education
Program/Adult Treatment Panel III (NCEP/ATP III),
3 the European Group for the study of Insulin Resistance (EGIR)
23 and the International
Diabetes Federation (IDF).
5
Component of metabolic syndrome WHO EGIR NCEP/ATP III IDF
Insulin resistance (IR) ++
Fasting blood glucose  ≥ 6.1 ≥ 6.1 ≥ 6.1 ≥ 5.6
(or impaired glucose tolerance)(mmol/L) (≥7.8  or type 2 diabetes)
Waist circumference (cm)  Men > 0.9 Men ≥ 94 Men > 102 Men  94
or waist / hip ratio (WHR) Women > 0.85 (WHR) Women ≥ 80 Women > 88 Women ≥ 80, 
ethnically specific values
Body mass index (kg/m
2) > 30
Triglycerides (mmol/L) ≥1.7 > 2.0 ≥ 1.7 ≥ 1.7 or specific therapy
HDL- cholesterol (mmol/L) Men < 0.9 < 1.0 Men < 1.04 Men < 1.02
Women < 1.0 Women < 1.29 Women < 1.29 or specific therapy
Blood pressure (mmHg) ≥ 140 / 90 ≥ 140 / 90 ≥ 130 / 85 ≥ 130 / 85 or specific therapy
Number of components IR or impaired fasting glucose  IR +≥2 others ≥ 3 Central obesity + 2 others
or glucose intolerance + 
≥ 2 others or microalbuminuria
Table 2. Definition of pediatric metabolic syndrome according to the International Diabetes
Federation.
Age (Years) Criteria for the metabolic syndrome
< 10 Obesity (waist circumference > 90
th percentile), 
metabolic syndrome as entity is not diagnosed
10-16 Waist circumference > 90
th percentile or adult 
cut-off if lower 
Triglycerides ≥ 1.7 mmol/L
HDL-cholesterol <1.03 mmol/L
Glucose ≥ 5.6 mmol/L or type 2 diabetes mellitus
Sistolic blood pressure ≥130 or diastolic blood 
pressure ≥ 85 mmHg
> 16 Adult criteria
For the diagnosis, central obesity and 2 of 4 other components must be present.
Table 3. Comparison of the metabolic syndrome criteria used in some pediatric studies. 
Metabolic syndrome Cook et al.
25 de Ferranti et al. 
11 Weiss et al.
26 Goodman et al.
27
components 
Fasting glucose ≥6.1 ≥6.1 Impaired glucose  ≥6.1, insulin 
(mmol/L) tolerance resistance
> 75
thpercentile(IR)
Waist circumference or  ≥ 90
thpercentile > 75
th percentile BMI z score > 2 males 102 cm females  88 cm
body mass index (BMI) for age and sex or BMI ≥95
thpercentile
Triglycerides  ≥ 1.2 ≥ 1.1 > 95
th ≥ 1.7
(mmol/l or percentiles) percentile
HDL-cholesterol  ≤ 1.04 < 1.2 (< 1.3 for < 5
th males ≤ 0.9     
(mmol/L or percentiles) ≤ boys 15-19 years) percentile females ≤ 1.01≤
Blood pressure ≥ 90
thpercentile ≥ 90
thpercentile ≥ 95
th  ≥ 130/85 mm Hg
percentile
Number of components ≥ 3 ≥ 3 ≥ 3 IR or type 2 diabetes + 2 others[Pediatric Reviews 2009;1:e1] [page 3]
for MS according to all the above-mentioned
mechanisms.
26
Abdominal  obesity  can  be  easy  assessed
using the simple measurement of waist cir-
cumference (WC) which is known to correlate
more strongly with visceral adipose tissue than
body mass index, another measure of obesity,
in both adults and children, and is a strong pre-
dictor  of  CV  risk  factors.
47,48 WC  percentile
nomograms  in  children  have  only  recently
become available for some ethnic groups,
49 but
are not available for all. In addition, there is no
internationally accepted classification of age
specific cut-off values. To overcome these lim-
itations, an index of the ratio between waist
and height has recently been proposed for clin-
ical  use,  as  it  does  not  require  percentile
tables. Several studies have shown that this
index is a good predictor of metabolic and CV
risks.
48,50
Dyslipidemia and metabolic 
syndrome  
Atherogenic dyslipidemia, namely elevated
triglycerides,  low  high-density  lipoprotein
(HDL)-cholesterol and small dense low-density
lipoprotein (LDL), is present in MS. Athero-
genic dyslipidemia is included in all published
definitions  of  MS.
2,3,4,5,23 Studies  have  shown
that the risk of dyslipidemia in predicting CV
risk is similar to that of high LDL-cholesterol.
51
Both excessive fat deposition and genetic pre-
disposition are involved in the development of
abnormal adipose tissue. When insulin resist-
ance blocks the inhibitory effect of insulin on
adipocyte  lipolysis,  adipocytes  increase  the
release of free fatty acids, which are transport-
ed to the liver. The liver incorporates free fatty
acids into triglycerides, which are assembled
into  very  low-density  lipoproteins.  Very  low-
density lipoproteins exchange triglycerides for
cholesteryl esters from LDL and HDL. Most of
the  cholesteryl  esters  return  to  the  liver  in
remnant  particles  after  very  low-density
lipoprotein triglycerides have been hydrolyzed
by  lipoprotein  lipase.  This  is  regarded  as  a
favorable effect. However, some of the choles-
teryl esters may end up in the arterial wall; the
proatherogenic  effect.  When  enriched  with
triglycerides, both HDL and LDL are subject to
lipolysis by hepatic lipase, resulting in smaller
particles.  Lipolyzed  HDL  particles,  which
exhibit an anti-atherogenic effect by partici-
pating in reverse cholesterol transport and by
antioxidant  mechanisms,  are  cleared  more
rapidly.  Small  dense  LDL  particles,  formed
after  lipolysis  of  triglyceride-rich  LDL,  are
atherogenic, probably due to increased pene-
tration  of  the  arterial  intima  and  decreased
antioxidant capacity.
15
Hypertension and metabolic 
syndrome
Hypertension is one of the important com-
ponents  of  MS.  The  relationship  between
hypertension  and  the  MS  is  complex,  most
probably because of its multifactorial nature.
An association between both hypertension and
body  weight  and  hypertension  and  insulin
resistance has been found in children.
52
Angiotensin  and  other  neurohormonal
mediators  of  hypertension  have  effects  on
Review
Table 4. Components of metabolic syndrome.
1. Insulin resistance*
2. Hyperinsulinemia*
3. Obesity: visceral (central), but also generalized obesity*
4. Dyslipidemia: high triglycerides, low HDL, small dense LDL*
5. Adipocyte dysfunction
6. Impaired glucose tolerance or type 2 diabetes mellitus*
7. Fatty liver (non-alcoholic steatohepatosis, steatohepatitis)
8. Essential hypertension: increased systolic and diastolic blood pressure*
9. Endothelial dysfunction 
10. Renal dysfunction (micro- or macroalbuminuria)
11. Polycystic ovary syndrome
12. Inflammation: increased CRP and other inflammatory markers
13. Hypercoagulability (increased fibrinogen and plasminogen activator inhibitor-1)
14. Atherosclerosis leading to increased cardiovascular morbidity and mortality*
*Most widely incorporated into the definition of metabolic syndrome..
Figure 1. Mechanism of the influence of obesity on cardiovascular diseases and type 2 diabetes.[page 4] [Pediatric Reviews 2009;1:e1]
intrarenal hemodynamics and renal electrolyte
handling, thus participating in blood pressure
control.  Increased  adipocyte  mass  leads  to
increased production of angiotensinogen, pro-
viding  a  potential  mechanism  for  increased
blood  pressure.
53 Adipocytes  also  produce
angiotensin–converting  enzyme  and  cathep-
sins, which effect local angiotensin conversion
and catabolism, and other substances of the
renin-angiotensin  system.
54,55 Angiotensin
itself promotes the growth of adipocytes.
54 Free
fatty  acids  have  been  shown  to  increase
angiotensinogen  production  and  promote
oxidative stress in endothelial cells, an effect
that is amplified by angiotensin.
53 Hyperinsu-
linemia may have a direct influence on elevat-
ed blood pressure by its activity on the sympa-
thetic nervous system
56 and by sodium reab-
sorption in the kidney.
57 In addition, it indirect-
ly  influences  mechanisms  important  for
vasodilation through nitric oxide release and
production of other vasodilators.
58 In one study
of children with hypertension, MF was found
in 17% of study subjects.
42 A recent extensive
assessment  of  various  metabolic  parameters
in a group of children found to have primary
hypertension  demonstrated  an  association
between left ventricular hypertrophy and MS in
hypertensive children.
59
Proinflammatory and prothrombo-
tic state and metabolic syndrome
Adipose  tissue  is  not  only  a  reservoir  for
energy but serves as an active secretory organ,
releasing peptides and cytokines into the circu-
lation.
14 In obesity, the dysregulated production
of adipocytokines has been found to participate
in the development of metabolic and CV dis-
eases.
60 Obesity is associated with subclinical
chronic inflammation.
61 In obese children, an
elevated level of CRP has been found 
62 and its
correlation with other MS components demon-
strated.
63 Values of CRP and interleukin-6 have
been found to correlate with the degree of obe-
sity,
26 insulin resistance and systolic blood pres-
sure.
61Adiponectin levels, reduced in obese chil-
dren, correlate negatively with body mass index,
levels of triglycerides and free fatty acids and
positively  with  insulin  sensitivity.
45 The  pro-
thrombotic state in MS arises from changes in
the  coagulation  and  fibrinolytic  systems,  in
thrombocytes and in vascular endothelial cells.
32
The most extensively studied factors associated
with  atherogenesis  are  fibrinogen  and  plas-
minogen  activator  inhibitor-1.
64 The  latter  is
also associated with type 2 diabetes.
65
Genetics and metabolic 
syndrome 
Most  of  the  components  of  MS,  such  as
hypertension and hypertriglyceridemia, as well
as associated abnormalities, are influenced by
genetic factors. Considering only the genetics of
insulin resistance, it can be said in summary,
that the clustering of insulin resistance in some
families has been well known for a long time.
66
Twin studies have shown that the influence of
genetic  factors  is  in  the  range  of  47-66%.
67
Mutations  in  genes  for  insulin  receptors,
68
defects in glucose transporter molecules
69 and
other  genetic  abnormalities  (e.g.  generalized
lipodystrophy)  are  associated  with  insulin
resistance.
70 These  genetic  abnormalities  are
important for a better understanding of insulin
resistance and for research into better treat-
ment options; however, they can only explain a
minor part of the genetic variability of insulin
resistance.  It  should  be  stressed  that  several
molecular  pathways  in  energy  homeostasis,
lipid metabolism, the insulin receptor signaling
pathway, cytokines, hormone-binding proteins
and other protease regulators are responsible
for the development of insulin resistance.
70
Some other important components
and metabolic syndrome
In  recent  years,  an  increasing  number  of
factors and diseases have been connected with
MS  and  even  proposed  as  its  components.
Some of them are presented in Table 4.
15
Non-alcoholic fatty liver disease (NAFLD),
characterized  by  the  accumulation  of  large
droplets of triglycerides within hepatocytes in
the absence of chronic alcohol consumption, is
the most common cause of pediatric liver dis-
ease.
71 It has been associated with obesity and
insulin  resistance.
72 In  addition,  studies  in
children have shown that it is strongly associ-
ated  with  multiple  CV  risk  factors  and  MS,
independently of body mass index, hyperinsu-
linemia
73 and the amount of visceral adipose
tissue, indicating that fat accumulation in the
liver may play a more important role than obe-
sity itself in determining the metabolic risk.
74
Moreover, fatty liver may prove to be a media-
tor of MS.
73 It is also associated with type 2 dia-
betes and advanced liver disease,
75 as well as
with carotid atherosclerosis.
76 The most impor-
tant therapeutic measure is increasing insulin
sensitivity  by  an  attempt  to  lose  weight.
Several  pharmacolological  agents  have  also
been used, mostly metformin.
77
A  number  of  studies  have  also  reported
strong association between concentrations of
uric acid and the MS or its components in both
adults
78and children,
79although uric acid is not
part of any definition of the MS. Uric acid has
also been associated with primary hyperten-
sion and a key role in its pathogenesis pro-
posed.
80 Moreover,  it  has  been  shown  that
allopurinol lowers uric acid and blood pressure
in  young  hypertensives.
80 In  obese  children,
the  association  with  carotid  atherosclerosis
has been demonstrated.
81
Endothelial dysfunction is thought to be one
of the earliest events in the development of
atherosclerosis and has also been associated
with MS in some studies.
82,83 Recent insights
into vascular biology have enabled us to under-
stand  the  molecular  mechanisms  underlying
endothelial dysfunction.
84 In studies, vascular
endothelial function has often been evaluated
using  measurement  of  brachial  artery  flow-
mediated  dilation  and  detection  of  selected
molecules, released by dysfunctional endothe-
lium.
85Numerous studies have been performed
in obese children, and functional and structur-
al  vascular  changes  identified.
85-87 Abdominal
adipose tissue accumulation has been associ-
ated with CV risk factors and with the elastic
properties  of  the  abdominal  aorta  in  obese
children.
88
Management of children with 
metabolic syndrome
Follow-up  of  adult  patients  with  MS  has
shown that, in every patient with a single CV
risk factor, all the other risk factors must be
sought  and  individually  treated.
7 At  present,
there are no unified consensus-based defini-
tion guidelines for the management of chil-
dren with MS, an important and urgent task for
the future,
89 although some preventive guide-
lines in cardiovascular health in childhood do
Review
Table 5. Metabolic effects of insulin and consequences of insulin resistance.
Normal insulin action Insulin-resistance state
Carbohydrates ‚Hepatic glucose production Hyperglycemia
ﾷGlucose utilization Hyperinsulinemia
ﾷGlycogenesis
Lipids ‚Lipolysis ﾷLipolysis
‚Free fatty acids and glycerol ﾷFree fatty acids and glycerol
ﾷLipogenesis ﾷHepatic triglyceride and apoB synthesis
ﾷHDL ‚HDL 
‚Triglycerides Hypertriglyceridemia
ﾷSmall dense LDL
Proteins ‚Gluconeogenesis ﾷGluconeogenesis
‚Amino acids ﾷProtein catabolism
ﾷProtein synthesis ‚Protein synthesis
Purines ﾷUric acid clearance Hyperuricemia
‚Uric acid formation[Pediatric Reviews 2009;1:e1] [page 5]
exist.
90The American Diabetes Association has
published guidelines for detection of children
with type 2 diabetes. Testing is recommended
for children with high-risk factors for type 2
diabetes, namely obesity, family history, high-
risk ethnic groups and clinical signs associat-
ed  with  insulin  resistance.
91 We  are  of  the
opinion  that  the  same  guidelines  should  be
applied to both adults and children. All children
with  essential  hypertension  are  managed
accordingly  in  our  department.
92 The  same
guidelines  have  been  proposed  by  the
American Heart Association.
89
A thorough family history and history of pre-
vious  diseases  and  present  difficulties  is
obtained  for  each  child.  The  importance  of
family history, which is an independent risk
factor
93 and which is associated with changes
in risk variables from childhood to adulthood,
must  be  stressed.
94,95 Examination  of  the
patient,  anthropometrical  measurements,
blood  pressure  measurement  and  laboratory
investigations are performed. Normal and cut-
off values of metabolic parameters for different
age groups in some populations are still prob-
lematic. For normal blood pressure values we
use  European  measurements.
96,97 Body  mass
index is used to establish obesity.
98 Normal val-
ues for waist circumference, which is a meas-
ure of abdominal obesity and directly associat-
ed  with  insulin  resistance,  have  been  pub-
lished for some populations.
49,99 Recently, a lin-
ear correlation between these two parameters
has been found in children, so both can be
used.
100For dyslipidemia, most researchers and
physicians use their own normal values.
101 For
glucose metabolism, in addition to fasting glu-
cose, fasting insulin is also determined and
the homeostasis model assessment of insulin
resistance  (HOMA–IR)  calculated.
102
Sometimes  an  oral  glucose  tolerance  test  is
also  performed.  Measurement  of  fasting
insulin  correlates  with  the  standard  eug-
lycemic  clamp  method  for  assessment  of
insulin  resistance,  which  is  expensive  and
time consuming.
103 The oral glucose tolerance
test is a good indicator of insulin resistance.
104
The importance of novel CV risk factors in
children has been investigated in some stud-
ies.
105 Although the positive predictive value of
some  of  the  parameters  has  already  been
demonstrated,  their  definitive  place  in  the
management of children with the MS has yet
to be defined. Studies have investigated the
role  of  CRP,
26,61-63,105,106 interleukin-6,
26,61 adipo-
nectine,
45,105,107,108 plasminogen  activator
inhibitor-1,
65 leptin,
105,109 homocysteine
110 and
others factors.
Treatment of children with 
metabolic syndrome
MS and related diseases are an important
public health problem. Therefore, for optimal
detection and management of patients, a glob-
al program is needed.
111 Preventive measures
must  be  instigated  in  childhood,  that  is,
healthy lifestyle education, with emphasis on
healthy  nutrition  and  physical  activity.  The
best prevention is prevention of the develop-
ment of obesity. Measurements of body weight,
body  height  and  blood  pressure  are  recom-
mended from the age of three years.
111 With
such management for each individual, CV risk
factors will be ascertained at an early stage,
the  total  CV  risk  determined  and  treatment
started when necessary. When one or more CV
risk factors are demonstrated in a child, treat-
ment  and  follow-up  are  started.  The  basic
treatment  always  consists  of  non-pharmaco-
logical  measures,  namely,  lifestyle  modifica-
tion  with  regular  physical  activity,  healthy
nutrition,  and  maintenance  of  the  recom-
mended  body  weight.  This  is  a  healthy
lifestyle, applicable to everybody. For healthy
nutrition,  the  daily  energy  intake  has  to  be
reduced and adjusted to body weight. The daily
diet must contain all essential components of
the  important  foodstuff  groups  in  five  daily
portions. The main aims of proper nutrition
are appropriate calorie intake, optimal nutri-
tion  for  health  maintenance  and  normal
growth, and maintenance of healthy nutrition
habits throughout life. Fat and protein intake
must be adapted to the age of the child (fat: for
children  from  1-3  years  old  30-40%  of  daily
calories,  for  older  children  25-30%;  protein:
from 1-3 years old 5-20%, for older children 10-
30%). Carbohydrates should be included in the
range  of  45-65%.  Saturated  fat  must  be
restricted (<10%), as well as cholesterol (<300
mg /day), salt (<6 g/day) and simple sugars.
Food must contain enough fiber (age of the
child + 5 g/day).
90
Lack of physical activity is one of the impor-
tant causes of the MS. Therefore, regular exer-
cise is vital. For improvement in insulin sensi-
tivity, at least 30-60 minutes of aerobic exer-
cise  daily  is  recommended.
90,112 In  addition,
exercises for strength, which diminish insulin
resistance, enlarge muscle mass and reduce
visceral adipose tissue, are advised.
113 Regular
physical activity can improve insulin sensitivi-
ty  by  40%.
114 It  has  been  demonstrated  that
eight  weeks  of  aerobic  exercises  improve
strength,  values  of  HDL  cholesterol  and
endothelial function.
115 Additionally, sedentary
activities must to be reduced to less than two
hours  per  day.
116 Physical  activity  and  diet
undoubtedly  play  important  roles  in  MS.
However, research with precise measurements
of  exercise,  diet  and  metabolic  outcomes  is
needed. 
It  has  been  shown  that  tobacco  exposure
independently influences the development of
MS.  Therefore,  prohibition  of  smoking  is
essential.
117
Both  parents  and  children  must  be  coun-
seled  and  educated.  The  whole  family  must
change their lifestyle habits, because CV risk
factors  cluster  in  families  as  a  result  of
unhealthy  lifestyle  and  genetic  factors.
Regular  follow-up,  education,  support  and
stimulation are necessary.
Management and treatment of children with
MS and its components also include various
intervention programs. School-based programs
are a notable example, highlighting the impor-
tance of developing a favorable environment
that promotes balanced eating behaviors and
extra-curricular  physical  activity.
118 Studies
also support family-based programs.
119
We should also stress the importance of psy-
chological aspects of MS in children. It seems
that MS and depressive symptoms are linked in
both directions. Namely, findings suggest that
psychological  characteristics,  especially
depression, hostility and anger, may increase
the risk for the MS.
120 On the other hand, it has
been  shown  that  MS  in  childhood  predicts
depressive  syndromes  in  adulthood.
121
Therefore, psychosocial prevention and treat-
ment interventions have to be included in the
management of these patients.
If  non-pharmacological  measures  are
unsuccessful, drug treatment should be con-
sidered.
Pharmacological treatment of obesity is lim-
ited. Sibutramin is effective, but its usage is
associated with side effects.
122 Orlistat treat-
ment is approved for treatment of obese ado-
lescents.
123 In several studies, the efficacy of
metformin was demonstrated in children with
MS, but its definitive role must be evaluated in
further studies, in particular its long-term effi-
cacy and safety.
124,125 Surgical treatment is lim-
ited to patients with a body mass index above
40 kg/m
2 and with associated diseases such as
obstructive apnea, type 2 diabetes and pseudo-
tumor cerebri.
126
Treatment of type 2 diabetes in adolescents
is the same as in adults.
127,128 In one study, 90%
of patients with the MS and type 2 diabetes
were treated with medications for blood sugar
control,  40%  with  antihypertensive  medica-
tions, and 10% with medication for fat reduc-
tion.
128
Guidelines for pharmacological treatment of
hypertension  include  symptomatic  hyperten-
sion, hypertensive target organ damage, stage
2  hypertension,  stage  1  hypertension  not
improving  after  non-pharmacological  meas-
ures, and hypertension with associated type 2
diabetes.
129,130 As first-line treatment, inhibitors
of the renin-angiotensin system (angiotensin-
converting  enzyme  inhibitors,  angiotensin
receptor blockers) or calcium channel blockers
are recommended. The former are the first-
line treatment in patients with associated type
2 diabetes or renal disease, especially if pro-
teinuria is present.
131,132
Treatment of dyslipidemia is started with a
low fat diet, especially with low saturated fat
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and cholesterol, a high fiber intake, addition of
phytosterols, body weight control and regular
physical activity. If these measures are unsuc-
cessful,  treatment  with  medications,  e.g.
statins is indicated, if there are no contraindi-
cations.
133 Well controlled studies of the effica-
cy, short-term safety and benefit of the statins
have been conducted in children
134 and recent-
ly  guidelines  for  treatment  have  been  pro-
posed.
135,136 However, for optimal treatment of
children with the MS, future studies, especial-
ly prospective studies, are needed.
137
Conclusion
CV  risk  factors,  comprising  the  MS,  do
appear  in  childhood,  eventually  progress  in
adulthood, and are associated with higher CV
morbidity in adults. In all children with a sin-
gle CV risk factor, all other known risk factors
should be determined. Each child with a single
detected CV risk factor must be treated individ-
ually, initially with non-pharmacological treat-
ment interventions. Children with several CV
risk factors are at higher risk, necessitating
meticulous follow-up and treatment. Children
with  MS  components  in  the  lower  normal
range are at a lower CV risk, indicating the
need for healthy lifestyle promotion in early
childhood. It should be stressed that primary
care doctors and nurses play an important role
in CV prevention and detection of individuals
with a higher CV risk. The MS must not be just
a new pediatric syndrome, but it should repre-
sent a challenge for better prevention strate-
gies.
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